Clinical Trials Details

S1418 (Breast)

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor Negative Breast Cancer with > or = to 1cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+)After Neoadjuvant Chemotherapy

Clinical Trial Categories

  • Cancers and Other Neoplasms